Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
Purpose
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Conditions
- Paroxysmal Atrial Fibrillation
- Persistent Atrial Fibrillation
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Symptomatic Paroxysmal (AF episode terminate spontaneously within 7 days) or Persistent (AF sustained beyond 7 days) who, in the opinion of the investigator, are candidates for ablation for AF - 18 years of age or older - De Novo ablation procedure unless it is a repeat for a patient whose index procedure is also in the registry - Able and willing to participate in baseline and follow up evaluations for the full length of the registry - Willing and able to provide informed consent, if applicable
Exclusion Criteria
- Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan - Long-standing persistent AF (AF greater than one year's duration) - Having a repeat ablation, unless the subject's index ablation procedure is also included in the registry - In the opinion of the investigator, any known contraindication to an ablation procedure
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Cohort
- Time Perspective
- Other
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Patients with atrial fibrillation | Subjects with symptomatic PAF or PsAF who, in the opinion of the investigator, are candidates for ablation for AF, age 18 years or older, and are able and willing to comply with all pre-, post-, and follow-up testing and requirements. |
|
Recruiting Locations
Birmingham, Alabama 35233
Michelle Osoinak
Birmingham, Alabama 35243
Susan Thorington
Mobile, Alabama 36695
Lynn Ward
Chandler, Arizona 85224
Gianani Cabrera
Jonesboro, Arkansas 72401
Kayla Rubino
Los Angeles, California 90033
Silvia Perez
Ventura, California 93303
Jennifer Freeland
Aurora, Colorado 80012
Chris Dutka
Golden, Colorado 80401
David Bailey
Littleton, Colorado 80120
Kathy Siegel
Jacksonville, Florida 32204
Jasmine Vestal
Miami, Florida 33133
Isabel Vital
Naples, Florida 34101
Anessa B Diers
Pensacola, Florida 32504
Ashley Corlies
Sarasota, Florida 34239
Colleen Linder
Winter Haven, Florida 33881
Lynda Argenzio
Atlanta, Georgia 30309
Mariam Nuhu
Savannah, Georgia 31404
Alta Castellino, BSN
Honolulu, Hawaii 97813
Beth Blackburn
Evanston, Illinois 60201
Marisa Durante
Springfield, Illinois 62704
Magen Kaler
Indianapolis, Indiana 46260
Anne Renick
Iowa City, Iowa 52242
Trisha Elliot
Louisville, Kentucky 40205
Tina Abell, RN, BSN
Saint Matthews, Kentucky 40207
Karin Cryan
Portland, Maine 04102
Joanne Burgess
Lanham, Maryland 20706
Iluyomade Adeusi
Boston, Massachusetts 02115
Deborah Manuelian
617-732-5087
Detroit, Michigan 48202
Briita Wanhala
Lansing, Michigan 48912
Jennifer Boak
Royal Oak, Michigan 48073
Greg Schlosser
Ypsilanti, Michigan 48197
Elizabeth Goetz
Jackson, Mississippi 39202
Sherrina N. Dixon
Columbia, Missouri 65212
Charles Donigian
Springfield, Missouri 65807
Sam Atkinson
Haddon Heights, New Jersey 08035
Kaitlyn Downey
Albuquerque, New Mexico 87102
Alexandra Ortiz
Poughkeepsie, New York 12601
Olatunde Olaniyi
Asheville, North Carolina 28801
Alex Boyd
Winston-Salem, North Carolina 27103
Patricia Reece
Cincinnati, Ohio 45202
Stephanie Byrd
Cincinnati, Ohio 45219
Anne Voorhorst
Columbus, Ohio 43213
Elissa VanKirk
614-546-4327
Oklahoma City, Oklahoma 73120
Terri Knight
Lancaster, Pennsylvania 17602
Andrew Hershey
Philadelphia, Pennsylvania 19104
Katie Shoemaker
Pittsburgh, Pennsylvania 15222
Caitlin Phalunas
York, Pennsylvania 17403
Elayne Grim
Greenville, South Carolina 29607
Ericka Calhoun
Dallas, Texas 75204
Kristina Perez
Dallas, Texas 75320
Corryn Weatherred
Salt Lake City, Utah 84124
Sherry Fisher
Lynchburg, Virginia 24501
Cindy Baumann
Midlothian, Virginia 23114
Kelly Patterson
Richmond, Virginia 23261
Ariana Dickens
Winchester, Virginia 22601
Janie Simpson
Tacoma, Washington 98405
Kari Davidson
Janesville, Wisconsin 53548
Kaitlyn Phetteplace, MSN
Madison, Wisconsin 53792
Torrey Tiedman
More Details
- NCT ID
- NCT04088071
- Status
- Recruiting
- Sponsor
- Heart Rhythm Clinical and Research Solutions, LLC
Detailed Description
The REAL AF Registry is an observational, prospective, multi-center, non-randomized registry designed to obtain real-world clinical experience of Paroxysmal and Persistent ablation RF technologies (e.g., THERMOCOOL SMARTTOUCH®, THERMOCOOL SMARTTOUCH® SF). Future new contact force technologies may be included as they become available in the market. Patient assessments will occur at the following time points: 1) pre-ablation, 2) procedure, 3) 10-12 weeks, 4) 6 months (monitor only) and 5) 1 year post ablation. The objective of this registry is to assess clinical outcomes, including procedural efficiency, safety, long-term, effectiveness of RF ablations in the treatment of patients with Paroxysmal or Persistent atrial fibrillation. The outcomes of the registry are: 1) long term effectiveness defined as freedom from atrial arrhythmia recurrence post 90 day blanking period, and 2) acute and late onset complications. Sites selected for this registry will already have the following pre and post procedure assessments as part of their standard of care: Patient assessments at the following time points: (1) pre-ablation or baseline, (2) procedure, (3) 10-12 weeks, (4) 6 months (monitor only) and (5) 1 year post ablation. Pre ablation/baseline assessment should include: TTE (within 6 months of procedure), CHADS2Vasc, sleep apnea, AAD status, OAC, Medical and Arrhythmia History 10-12 Week Follow-Up Office Visit: Physician evaluation, AAD status, OAC usage, repeat TTE, and Arrhythmia Reoccurrence and Treatment Assessment Monitoring: 96-hour continuous heart rhythm monitor scheduled at 6 months and 12 months post ablation, with an event monitor ordered as needed for symptomatic arrhythmias. 12 Month Follow up Office Visit: Physician evaluation, AF Type, AF Monitoring method, Sleep apnea, Post-procedure arrhythmia treatments, AF related symptoms and QOL improvement, AAD and OAC usage, CHA2DS2VASC and Arrhythmia Reoccurrence and Treatment Assessment